327 related articles for article (PubMed ID: 25393506)
1. Clinical application of asparaginase activity levels following treatment with pegaspargase.
Bleyer A; Asselin BL; Koontz SE; Hunger SP
Pediatr Blood Cancer; 2015 Jun; 62(6):1102-5. PubMed ID: 25393506
[TBL] [Abstract][Full Text] [Related]
2. Desensitization to pegaspargase in children with acute lymphoblastic leukemia and lymphoblastic lymphoma.
August KJ; Farooki S; Fulbright JM; August A; Portnoy JM; Pommert L; Burke MJ; Guest EM
Pediatr Blood Cancer; 2020 Jan; 67(1):e28021. PubMed ID: 31571395
[TBL] [Abstract][Full Text] [Related]
3. FDA drug approval summary: pegaspargase (oncaspar) for the first-line treatment of children with acute lymphoblastic leukemia (ALL).
Dinndorf PA; Gootenberg J; Cohen MH; Keegan P; Pazdur R
Oncologist; 2007 Aug; 12(8):991-8. PubMed ID: 17766659
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic and clinical considerations for monitoring asparaginase activity levels during pegaspargase therapy.
Benitez L; Perissinotti AJ; Santarossa M; Marini BL
Pediatr Blood Cancer; 2015 Jun; 62(6):1115. PubMed ID: 25649118
[No Abstract] [Full Text] [Related]
5. Pegaspargase for acute lymphoblastic leukemia.
Med Lett Drugs Ther; 1995 Mar; 37(944):23-4. PubMed ID: 7877556
[No Abstract] [Full Text] [Related]
6. Pegaspargase: an alternative?
Holle LM
Ann Pharmacother; 1997 May; 31(5):616-24. PubMed ID: 9161659
[TBL] [Abstract][Full Text] [Related]
7. Reply to: Colon LB, Perissinotti A, Santarosa M, Marini BL. Pharmacokinetic and clinical considerations for monitoring asparaginase activity levels during pegaspargase therapy.
Pediatr Blood Cancer; 2015 Jun; 62(6):1116. PubMed ID: 25732374
[No Abstract] [Full Text] [Related]
8. Asparaginase Erwinia chrysanthemi (Erwinaze®): a guide to its use in acute lymphoblastic leukemia in the USA.
Keating GM
BioDrugs; 2013 Aug; 27(4):413-8. PubMed ID: 23794007
[TBL] [Abstract][Full Text] [Related]
9. Asparaginase activity levels and monitoring in patients with acute lymphoblastic leukemia.
Salzer W; Bostrom B; Messinger Y; Perissinotti AJ; Marini B
Leuk Lymphoma; 2018 Aug; 59(8):1797-1806. PubMed ID: 29045165
[TBL] [Abstract][Full Text] [Related]
10. Plasma asparaginase activity and asparagine depletion in acute lymphoblastic leukemia patients treated with pegaspargase on Children's Oncology Group AALL07P4
Schore RJ; Devidas M; Bleyer A; Reaman GH; Winick N; Loh ML; Raetz EA; Carroll WL; Hunger SP; Angiolillo AL
Leuk Lymphoma; 2019 Jul; 60(7):1740-1748. PubMed ID: 30626253
[TBL] [Abstract][Full Text] [Related]
11. Pegaspargase.
Alfieri DR
Pediatr Nurs; 1995; 21(5):471-4, 490. PubMed ID: 8684851
[TBL] [Abstract][Full Text] [Related]
12. PEG-linked asparaginase marketed.
Am J Hosp Pharm; 1994 Jun; 51(11):1382. PubMed ID: 7942872
[No Abstract] [Full Text] [Related]
13. Clinical decisions following implementation of asparaginase activity monitoring in pediatric patients with acute lymphoblastic leukemia: Experience from a single-center study.
Nadeem K; Colantonio D; Kircanski I; Naqvi A; Hitzler J; Whitlock JA; Dupuis LL
Pediatr Blood Cancer; 2020 Feb; 67(2):e28044. PubMed ID: 31625674
[TBL] [Abstract][Full Text] [Related]
14. The use of Erwinia asparaginase for adult patients with acute lymphoblastic leukemia after pegaspargase intolerance.
Horvat TZ; Pecoraro JJ; Daley RJ; Buie LW; King AC; Rampal RK; Tallman MS; Park JH; Douer D
Leuk Res; 2016 Nov; 50():17-20. PubMed ID: 27631159
[TBL] [Abstract][Full Text] [Related]
15. [Therapeutic alternatives to native L-asparaginase in the treatment of adult acute lymphoblastic leukemia].
Thomas X; Cannas G; Chelghoum Y; Gougounon A
Bull Cancer; 2010 Sep; 97(9):1105-17. PubMed ID: 20693115
[TBL] [Abstract][Full Text] [Related]
16. Pegaspargase versus asparaginase in adult ALL: a pharmacoeconomic assessment.
Peters BG; Goeckner BJ; Ponzillo JJ; Velasquez WS; Wilson AL
Formulary; 1995 Jul; 30(7):388-93. PubMed ID: 10151730
[TBL] [Abstract][Full Text] [Related]
17. Peg-asparaginase for acute lymphoblastic leukemia.
Rytting M
Expert Opin Biol Ther; 2010 May; 10(5):833-9. PubMed ID: 20345338
[TBL] [Abstract][Full Text] [Related]
18. Consensus expert recommendations for identification and management of asparaginase hypersensitivity and silent inactivation.
van der Sluis IM; Vrooman LM; Pieters R; Baruchel A; Escherich G; Goulden N; Mondelaers V; Sanchez de Toledo J; Rizzari C; Silverman LB; Whitlock JA
Haematologica; 2016 Mar; 101(3):279-85. PubMed ID: 26928249
[TBL] [Abstract][Full Text] [Related]
19. [Advances on the role of pegaspargase in the treatment of childhood leukemia].
Liu L; Xie XT
Zhongguo Dang Dai Er Ke Za Zhi; 2014 Feb; 16(2):155-60. PubMed ID: 24568909
[TBL] [Abstract][Full Text] [Related]
20. Pegaspargase: a review of clinical studies.
Graham ML
Adv Drug Deliv Rev; 2003 Sep; 55(10):1293-302. PubMed ID: 14499708
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
